Highly active antiretroviral therapy induced drug-drug interactions in Indian Human Immunodeficiency virus positive patients

International Journal of PharmTech Research

Volumn 3, Issue 2, 2011, Pages 678-692

  Rajesh, Radhakrishnan ^a   Vidyasagar, Sudha ^b  

^a MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^b KASTURBA MEDICAL COLLEGE   (India)

Author keywords

Drug drug reactions; Highly active antiretroviral therapy; Human immunodeficiency virus

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE;

ANEMIA; ARTICLE; DISEASE SEVERITY; DRUG SURVEILLANCE PROGRAM; ERYTHROCYTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; RISK ASSESSMENT; RISK FACTOR; TUBERCULOSIS;

EID: 84856279767     PISSN: None     EISSN: 09744304     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. World Health Organization [home page on the internet]. Available from: URL:http://www.who.int/en/ (accessed 23 October 2008).
2. Averting HIV and AIDS [home page on the internet]. 2008 November 26.Available from: URL:http://www.avert.org/ (accessed 5 January 2009).
3. Sanderson N. Drug-drug interactions: the silent epidemic Psychiatr Serv 2005; 56: 22-4.
4. Cooper CL, Breau C, Laroche A, et al. Clinical outcomes of first antiretroviral regimen in HIV/hepatitis C virus co-infection. HIV Med 2006; 7(1): 32-37.
5. Shah S, Gowan J, Opulski B et al. Identification of drug interactions involving ART in New York City HIV specialty clinics. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007. Abstract 573, p. 277. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
6. Maat M, De Boer A, Koks C et al. Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. J Clin Pharm Ther 2004; 29: 121-30.
7. Bachani D. 650 link ART centres planned under NACP-III. NACO News 2009; 5(1): 8.
8. National AIDS Control Organization. Ministry of Health and Family Welfare, Government of India. [home page on the internet]. 2009 August 26.Available from: URL:https://nacoonline.org/NACO (accessed 31 August 2009).
9. WHO. Antiretroviral WHO. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach 2006. Available from http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf. (accessed 19 August 2006).
10. Tatro DS, ed. Drug Interaction Facts. St Louis, Miss.: Facts and Comparisons, 2005: 1-1699.
11. Kashuba DM. Drug-Drug Interactions and the Pharmacotherapy of HIV Infection. HIV Med. 2005; 13(2):64-69.
12. Fong OW. Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients. HIV Med 2003; 4:133-138.
13. Gerber JG. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection. CID 2000; 30 (Suppl 2): S123-S129.
14. De Lorenze G, Follansbee S, Nguyen D et al. Medication error in the care of HIV/AIDs patients-electronic surveillance, confirmation and adverse events. Med Care 2005; 43 Suppl 9:63-68
15. Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet.1999; 36,289-304.
16. Chadwick B, Waller DG, Edwards JG, et al. Potentially hazardous drug interactions with psychotropics. Advances in Psychiatric treatment. 2005; 11:440-449.
17. Hussar DA, Marderosian AHD, Hanson GR, et al. Drug interaction. In Remington The science and practice of pharmacy. Philadelphia: Lippincott Williams & Wilkins, 2000: 1746-1761.
18. Katende NL, Lubbe MS, Serfontein JHP, et al. Prevalence of drug-drug interactions of antiretroviral agents in the private health care sector in South Africa. SAMJ.2008; 98(2):109-113.
19. Pau AK. Polypharmacy Problems: Drug interactions in the multidrug therapy of HIV infection. The PRN notebook.2002; 7(1):4-9.
20. Johnson MD, Newkirk G, White JR et al. Clinically significant drug interactions: what you need to know before writing prescriptions. Postgrad Med. 1999; 105:193-206.
21. Sedan K, Back D, Khoo S, et al. Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable. Journal of Antimicrobial Chemotherapy 2009; 64:5-8.
22. Acosta EP. Pharmacokinetic enhancement of protease inhibitors. J Acquir Immune Defic Syndr, 2002. 29 (Suppl 1):S11-8.
23. Greenblatt RM, Hollander H, McMaster JR, et al. Polypharmacy among patients attending an AIDS clinic; utilization of prescribed,unorthodox,and investigational treatments, J Acquir Immunodefic Syndr 1991;4:136-143.
24. Harb G, Alldredge B, Coleman E, et al. Pharmacoepidemiology of adverse drug reactions in hospitalized patients with human immunodeficiency virus disease. J Acquir Immunodefic Syndr 1993; 8:919-926.
25. Centers for Disease Control and Prevention Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or non nucleoside reverse transcriptase inhibitors; 2004. Version 1.20.04. http://www.nccc.ucsf.edu/Clinical_Resources/Guidelines/PDFs/tbhiv.pdf. (accessed 11 July 2008).
26. Centers for Disease Control and Prevention. Managing Drug Interactions in the treatment of HIV Related Tuberculosis. 2007. http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm. PublishedDecember 2007. (accessed 11July 2008).
27. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med, 2001. 344(13):984-96.
28. Boulle A, Zweigenthal V, Hilderbrand K, et al. Incidence of tuberculosis pre- and post-ART in a setting of high tuberculosis-HIV comorbidity. Paper presented at: 15th International AIDS Conference. July 11-16, 2004; Bangkok, Thailand; 2004. Abstract MoPeB 3239.
29. Lawn SD, Myer L, Bekker LG, et al. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006; 20(12):1605-1612.
30. Brinkhof MW, Egger M, Boulle A, et al. Tuberculosis after initiation of antiretroviral therapy in low income and high-income countries. Clin Infect Dis. 2007; 45(11):1518-1521.
31. Corbett EL, Marston B, Churchyard GJ, et al. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet. 2006; 367(9514):926-937.
32. Hoffmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS. 2007; 21(10):1301-1308.
33. Norah LKK, Lubbe MS, Serfontein JHP, et al. Effect of prescribed minimum benefits on the prevalence of possible drug-drug interactions of antiretroviral agents in a section of the private health care sector in South Africa: A two year comparative study. Int J Pharm Pract. 2008; 16:403-408.
34. Sabo JP, Lamson MJ, Leitz G, et al. Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. AAPS PharmSci. 2000, 2 E1-E7.
35. Epivir (Lamivudine). GlaxoSmithKline UK.UK Summary of product characteristic, March 2007.